Subcutaneous Opdivo showed comparable effectiveness, safety and tolerability to IV Opdivo in advanced clear cell renal cell ...

Erleada reduced the risk of death by more than 20% compared with other treatments in metastatic castration-sensitive prostate ...

What is lovely never dies, but passes into other loveliness, Stardust or seafoam, flower or winged air. ― Thomas Bailey Aldrich ...

Pheast Therapeutics has treated the first patient in a phase 1 trial of PHST001, a novel macrophage checkpoint inhibitor for advanced solid tumors.

A phase 2a clinical trial of NEO100-01 is continuing to recruit patients with malignant gliomas, with full enrollment expected in September.

Melanoma is a key cancer type for developing and testing immunotherapies prior to broader clinical application across other malignancies.